



Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve survival and quality of life for patients with cancer.




Record of identification of promising oncology assets and in-license under favorable terms



Proven ability to develop & efficiently execute targeted clinical development strategies in solid and hematologic malignancies



Establishing a commercial capability in the US, initially focused on lymphoid malignancies



\* - Investigator Sponsored Trial (IST)  
Duvelisib and defactinib are investigational agents available for clinical trial use only. Safety and efficacy have not been established.

### CLINICAL AND SCIENTIFIC ADVISORY BOARD

**Robert Weinberg, Ph.D.**  
Co-founder & Chairman of CSAB  
Whitehead Institute/MIT

**Greg I. Berk, M.D.**  
Former Executive/CMO - Verastem, Sideris, BIND  
Intellikine, Abraxis Biosciences

**Edmund J. Pezalla, M.D., Ph.D.**  
Former VP - Pharmaceutical Policy and Strategy at Aetna  
Scholar in Residence - Duke-Margolis Health Policy Center

**Cheryl Cohen**  
BOD - Tokai, Protein Sciences, Vital  
Former CCO - Medivation (Xtandi®)

**Steve Sherwin, M.D.**  
UCSF, San Francisco General Hospital  
Director - Biogen Idec, Neurocrine Biosciences, Rigol

**Paul Friedman, M.D.**  
CEO Madrigal (SNTA), Former President/CEO  
Incyte (INCY)

**Brian Stuglik, R.Ph.**  
Former VP and Chief Marketing Officer - Oncology Global  
Marketing, Eli Lilly & Co.

**Lori Kunkel, M.D.**  
BOD - Loxo Oncology  
Former Executive/CMO - Pharmacyclics,  
Proteolix, Xencor

**Max Wicha, M.D.**  
Director - University of Michigan Comprehensive Cancer  
Center

**Verastem Inc.**  
117 Kendrick Street, Suite 500  
Needham, MA 02494  
(781) 292 - 4200  
www.verastem.com

### EXECUTIVE LEADERSHIP

**Robert Forrester**  
President/CEO, BOD

**Daniel Paterson**  
Chief Operating Officer

**Steven Bloom**  
Senior VP, Corporate Development

**Cathy Carew**  
VP, Human Resources

**Julie Feder**  
Chief Financial Officer

**Diep Le, M.D., Ph.D.**  
Chief Medical Officer

**Jonathan Pachter, Ph.D.**  
Chief Scientific Officer

**Hagop Yousouffian, M.Sc., M.D.**  
Head of Hematology and Oncology

### BOARD OF DIRECTORS

**Michael Kauffman, M.D., Ph.D.**  
Lead Director

CEO Karyopharm (KPTI), former CMO Onyx

**Timothy Barberich**  
Former CEO/Chair Sepracor (SEPR)

**Eric Rowinski, M.D.**  
CSO ClearPath, Former CMO ImClone Erbitux®,  
Taxotere®, Tarceva®

**Bruce Wendel**  
CSO Hepalink USA, former CEO Abraxis  
BioScience

**Alison Lawton**  
Former Genzyme (now Sanofi)

**Louise Phanstiel**  
BOD: Cedars Sinai, MYGN

**Brian Stuglik, R.Ph.**  
Former Chief Marketing Officer - Lilly Oncology

**NASDAQ: VSTM**  
(as of 10/2/2017)

Price: \$3.55

Market cap: \$141M

52 week range: \$1.05 - 5.71

3 month average volume: 1.2m

Ordinary shares outstanding: 39.9M

**CASH BALANCE**

(Pro-forma as of 9/30/2017)

# DUVELISIB AND DEFACTINIB – KEY CLINICAL TRIALS ONGOING TO EVALUATE SAFETY AND EFFICACY

## DUVELISIB

<b>Mechanism</b>	Dual inhibitor of PI3K- $\delta$ (delta) and PI3K- $\gamma$ (gamma)
<b>RP2D</b>	25 mg BID. Oral
<b>IP</b>	COM 2030 before extensions
<b>Orphan designation</b>	CLL, SLL and FL in the US and EU
<b>FDA Fast Track Designation</b>	<ul style="list-style-type: none"> <li>Patients with follicular lymphoma who have received at least two prior therapies</li> <li>Patients with CLL or PTCL who have received at least one prior therapy</li> </ul>

Dual PI3K- $\delta,\gamma$  inhibitor with positive Phase 2 data in iNHL and Phase 3 data in CLL  
Potential applicability in other lymphoid malignancies

## DEFACTINIB

<b>Mechanism</b>	Dual inhibitor of FAK and PYK2
<b>RP2D</b>	400 mg BID. Oral
<b>IP</b>	COM 2028 before extensions
<b>Orphan designation</b>	Ovarian and mesothelioma in the US and EU

FAK inhibitor in combination studies with leading immuno-oncology agents for the treatment of multiple solid tumors

### DUVELISIB in iNHL



Study end points	
• Primary:	Overall response rate (ORR) by Independent Review Committee (IRC)
• Key secondary:	<ul style="list-style-type: none"> <li>Safety</li> <li>Duration of response (DOR)</li> <li>Progression-free survival (PFS)</li> <li>Overall survival (OS)</li> </ul>

- \* Heavily pretreated patient population:
- Median number of prior treatments = 3
  - Inclusion criteria: Refractory to both rituximab (R) and a chemotherapy regimen or radioimmunotherapy (RIT)


- Primary analysis (6 month follow up) presented at ASH 2016  
- Long-term analysis (18 month follow up) presented at ICMC 2017

#### Primary endpoint:


- ORR by IRC at per-protocol final analysis: (p=0.0001)

#### Secondary endpoints:


- Median PFS on duvelisib: 8.4 months
- Median DOR: 10 months



83% of patients had reduction in target lymph nodes per IRC



### DUVELISIB in CLL



POSITIVE PHASE 3 STUDY, TOP LINE DATA ANNOUNCED SEPTEMBER 2017

Study end points	
• Primary:	Progression-free survival (PFS)
• Secondary:	<ul style="list-style-type: none"> <li>Overall response rate (ORR)</li> <li>Overall survival (OS)</li> <li>Duration of response (DOR)</li> <li>Safety</li> </ul>

DUO™ met its primary endpoint of PFS by IRC in both the ITT and del(17p) subpopulation

#### DUO™ TOP LINE DATA

	Duvelisib	Ofatumumab
PRIMARY ENDPOINT: PROGRESSION-FREE SURVIVAL (PFS) BY IRC		
ITT population, median	13.3 months	9.9 months
	HR = 0.52; p < 0.0001	
del(17p) subset, median	12.7 months	9.0 months
	HR = 0.41; p = 0.0011	

Duvelisib monotherapy had a manageable safety profile, with results from this study consistent with the well-characterized safety profile of duvelisib monotherapy observed to date in patients with advanced hematologic malignancies.


Detailed results to be presented at ASH 2017 on Sunday, December 10<sup>th</sup> at 4:30pm ET

### DEFACTINIB in I-O COMBINATIONS

FAK inhibition **boosts immune attack**, supporting combination with immunotherapies



FAK inhibition **reduces stromal density**, enabling therapies & immune cells to penetrate tumors



**Pfizer** **MERCK**  
Ongoing combination trial with avelumab (Ovarian)

**MERCK**  
2 ongoing combination trials with pembrolizumab (NSCLC, pancreatic, mesothelioma)

**CANCER RESEARCH UK**  
First cross-company deal as part of Experimental Cancer Medicine Centre (ECMC) Combinations Alliance

**Washington University in St. Louis**  
Active pre-clinical to clinical translation of I-O combinations